Research Analysts Offer Predictions for Amarin Q2 Earnings

Key Points

• Zacks Research has cut Amarin's Q2 2025 earnings estimate from ($0.60) to ($0.79) per share.
• Amarin reported earnings of ($0.03) per share for the latest quarter, exceeding expectations of ($0.60) by $0.57.
• The stock has recently experienced target price changes, with Goldman Sachs raising it to $12.00 while maintaining a "sell" rating.

Amarin Corporation PLC (NASDAQ:AMRN - Free Report) - Equities researchers at Zacks Research reduced their Q2 2025 earnings per share estimates for shares of Amarin in a note issued to investors on Tuesday, July 29th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of ($0.79) per share for the quarter, down from their previous forecast of ($0.60). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q3 2025 earnings at ($0.77) EPS, Q4 2025 earnings at ($0.90) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.79) EPS, FY2026 earnings at ($1.93) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at $0.26 EPS and FY2027 earnings at ($0.91) EPS.

Amarin (NASDAQ:AMRN - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.63. The business had revenue of $72.74 million for the quarter, compared to the consensus estimate of $45.45 million. Amarin had a negative return on equity of 21.18% and a negative net margin of 47.22%.

AMRN has been the topic of a number of other research reports. Wall Street Zen upgraded Amarin from a "hold" rating to a "buy" rating in a research report on Saturday. The Goldman Sachs Group increased their price target on Amarin from $7.00 to $12.00 and gave the stock a "sell" rating in a research report on Wednesday, June 25th.

Amarin Price Performance

Amarin stock traded up $0.13 during trading hours on Thursday, hitting $15.29. 22,752 shares of the stock traded hands, compared to its average volume of 96,404. The firm's 50 day moving average price is $14.46 and its 200-day moving average price is $11.76. The stock has a market capitalization of $316.51 million, a price-to-earnings ratio of -4.17 and a beta of 0.84. Amarin has a 1 year low of $7.08 and a 1 year high of $17.49.

Institutional Trading of Amarin

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Banque Cantonale Vaudoise purchased a new stake in Amarin in the 1st quarter valued at approximately $25,000. Kornitzer Capital Management Inc. KS boosted its stake in shares of Amarin by 4.0% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company's stock worth $40,000 after acquiring an additional 3,400 shares in the last quarter. Generation Capital Management LLC purchased a new stake in shares of Amarin during the 4th quarter worth approximately $50,000. Stonepine Capital Management LLC purchased a new stake in shares of Amarin during the 4th quarter worth approximately $55,000. Finally, LPL Financial LLC boosted its stake in shares of Amarin by 26.0% during the 4th quarter. LPL Financial LLC now owns 153,020 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 31,555 shares in the last quarter. Institutional investors and hedge funds own 22.25% of the company's stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.